Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....
In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles' fibroblasts. This research, conducted by a team of dedicated scientists from the...
For children diagnosed with complex heart conditions like hypertrophic cardiomyopathy (HCM), the diagnosis can be frightening for families and challenging for healthcare providers since the trajectory of the condition is often uncertain. As a leading cause of sudden...
An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
Several members of the Ted Rogers Centre for Heart Research (TRCHR) participated in Vascular 2023, a five-day conference held in Montreal from October 25-29. The conference is a hallmark event organized by several Canadian specialist and research organizations,...
Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
Experts in our Cardiac Genome Clinic have developed a bioinformatics tool that you can use to assess whole genome and whole exome sequencing data, and better identify genetic variants that are causing disease.
“GeneTerpret” is a flexible platform designed to streamline the genome interpretation process, through a unique interface, with improved ease, speed and accuracy. Upload data, filter it using integrated databases, and receive a priority list of the highest-potential disease-causing genes or variants in that particular patient.
GeneTerpret greatly reduces the time and labour often required to comb through databases, clinical histories and available literature in order to analyze a sample. GeneTerpret has the potential to save hours on each case, freeing analysts to spend more time hunting for new disease-related genes.
An open access study describing this tool and its achievements is published in February 2022.